These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37181967)

  • 1. Assessing the Correlation of Rate of Pathological Complete Response and Outcome in Post Neoadjuvant Chemotherapy Setting and Molecular Subtypes of Breast Cancer.
    Omair A; Alkushi A; Alamri G; Almojel T; Alsadun S; Masuadi E; Arabi H; Mohamed AE; Abulkhair OA
    Cureus; 2023 Apr; 15(4):e37449. PubMed ID: 37181967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer.
    Fang Y; Zhang Q; Wu Y; Wu J
    Medicine (Baltimore); 2024 Feb; 103(6):e37170. PubMed ID: 38335419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Luminal B, Human Epidermal Growth Factor Receptor 2 (HER2/neu), and Triple-Negative Breast Cancers Associated With a Better Chemotherapy Response Than Luminal A Breast Cancers in Postneoadjuvant Settings.
    Hashmi AA; Bukhari U; Najam J; Dowlah T; Ali AH; Diwan MA; Anjali F; Sham S; Zia S; Irfan M
    Cureus; 2023 Jun; 15(6):e40066. PubMed ID: 37425505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
    Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy before Surgery: A Retrospective Analysis.
    Zhang S; Liu Y; Liu X; Liu Y; Zhang J
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
    Alves FR; Gil L; Vasconcelos de Matos L; Baleiras A; Vasques C; Neves MT; Ferreira A; Fontes-Sousa M; Miranda H; Martins A
    Cureus; 2022 Feb; 14(2):e22330. PubMed ID: 35371692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy.
    Cabrera-Galeana P; Muñoz-Montaño W; Lara-Medina F; Alvarado-Miranda A; Pérez-Sánchez V; Villarreal-Garza C; Quintero RM; Porras-Reyes F; Bargallo-Rocha E; Del Carmen I; Mohar A; Arrieta O
    Oncologist; 2018 Jun; 23(6):670-678. PubMed ID: 29490940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer.
    Zhang GC; Zhang YF; Xu FP; Qian XK; Guo ZB; Ren CY; Yao M
    Curr Oncol; 2013 Jun; 20(3):e180-92. PubMed ID: 23737688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer - a Single Centre Study. (PPLB - 01).
    Agrawal S; Banswal L; Saha A; Arun I; Datta SS; Chatterjee S; Ahmed R
    Indian J Surg Oncol; 2016 Dec; 7(4):397-406. PubMed ID: 27872526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy.
    Gómez R; Ossa CA; Montoya ME; Echeverri C; Ángel G; Ascuntar J; Borrero M; Gil M; Herrera S; Gutiérrez E; Herazo F; Jiménez A; Madrid J; Reyes PA; Zuluaga L; García H
    Ecancermedicalscience; 2015; 9():562. PubMed ID: 26316883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer subtypes can be a predictor of pathologic complete response and survival in the neoadjuvant setting for T4 noninflammatory breast cancer.
    Gülben K; Berberoğlu U; Kinaş V; Başkan E
    Acta Chir Belg; 2014; 114(3):153-9. PubMed ID: 25102703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Predictive values of pathologic complete response for patient outcome in different molecular subtypes of breast cancer].
    Liu W; Li JB; Wang T; Bian L; Zhang SH; Zhang HQ; Zhou JM; Song ST; Jiang ZF
    Zhonghua Yi Xue Za Zhi; 2016 Sep; 96(36):2898-2902. PubMed ID: 27760635
    [No Abstract]   [Full Text] [Related]  

  • 16. Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2- Breast Cancer: Impact of Tumor Ki67 and ER Status.
    Akdag G; Yildirim S; Dogan A; Yuksel Yasar Z; Bal H; Kinikoglu O; Oksuz S; Ozkerim U; Tunbekici S; Yildiz HS; Turkoglu E; Alan O; Coban Kokten S; Isik D; Sever ON; Odabas H; Yildirim ME; Turan N
    Chemotherapy; 2024 Feb; ():. PubMed ID: 38368871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients.
    Luangdilok S; Samarnthai N; Korphaisarn K
    J Breast Cancer; 2014 Dec; 17(4):376-85. PubMed ID: 25548587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
    Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
    Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.
    Ohzawa H; Sakatani T; Niki T; Yasuda Y; Hozumi Y
    Breast Cancer; 2014 Sep; 21(5):563-70. PubMed ID: 23108629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response.
    Resende U; Cabello C; Ramalho SOB; Zeferino LC
    BMC Cancer; 2019 Jun; 19(1):601. PubMed ID: 31208353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.